ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the appointment of Sarah J. Schlesinger, M.D., senior attending physician and associate professor of clinical investigation in the Laboratory of Cellular Physiology and Immunology at The Rockefeller University, to its Board of Directors. Dr. Schlesinger, 53, is a prominent clinical investigator and immunologist who has spent more than 20 years working in the field of cellular immunity, including as clinical director of the laboratory led by the late Ralph M. Steinman, M.D., 2011 Nobel Laureate in Physiology or Medicine.
ARIAD Names Sarah J. Schlesinger, M.D. of Rockefeller University to Its Board of Directors (Photo: Business Wire)
“Dr. Schlesinger brings a deep understanding of translational medicine, clinical research, and immunology to our Board of Directors,” stated Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD. “Sarah embodies one of our most important corporate values – clinical scholarship – and further enhances our commitment to cancer patients in need of new therapies. We anticipate that she will contribute greatly to our Board and to the evolution of our long-term strategy, especially as the fields of molecularly targeted therapy and immunotherapy converge.”
Dr. Schlesinger’s research has focused on the clinical manipulation of the immune system’s dendritic cells to elicit immunity to cancer and HIV. Working closely with Dr. Steinman, she used dendritic cells to study and design novel treatments that may be able to harness the immune system in a disease-specific approach. She has designed and conducted clinical trials employing the techniques of immunology and dendritic-cell biology, which have led to a better understanding of human diseases and their potential treatments.
In addition to leading clinical trials at the Rockefeller University Hospital, she is co-director of the University’s Clinical Scholars program and the Certificate in Clinical and Translational Sciences program. She chairs the research education and training committee of the Center for Clinical and Translational Science at Rockefeller. Widely published in her field, Dr. Schlesinger has been recognized with numerous awards for her research and teaching.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts